Canine malignant melanoma (CMM) is the most common canine oral tumour, and up to 70-75% of dogs in stage II-III die within 1 year after surgery. The purpose of this study was to evaluate the expression of platelet-derived growth factors receptors (PDGFR)-α and -β in stage II and III CMMs and to correlate it with prognosis. PDGFRs expression was evaluated by immunohistochemistry on 48 cases of formalin-fixed CMM samples and correlated with clinical-pathological findings and outcome after surgery. PDGFRs co-expression was observed in 37.5% of cases. Positivity for PDGFR-α and -β receptor was present in 54.2 and 47.9% of cases, respectively. Ki67 values >19.5% were ascertained in 66.7% of cases. Statistical analysis showed that PDGFRs co-expression and Ki67 values > 19.5% were both associated with worse prognosis. PDGFRs expression suggests a role in the pathogenesis and progression of CMM, and α and β co-expression appears to be associated to worse prognosis

PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis

IUSSICH, Selina;MANISCALCO, LORELLA;IOTTI, BRYAN;MORELLO, Emanuela Maria;MARTANO, Marina;GATTINO, FRANCESCA;BURACCO, Paolo;DE MARIA, RAFFAELLA
2017-01-01

Abstract

Canine malignant melanoma (CMM) is the most common canine oral tumour, and up to 70-75% of dogs in stage II-III die within 1 year after surgery. The purpose of this study was to evaluate the expression of platelet-derived growth factors receptors (PDGFR)-α and -β in stage II and III CMMs and to correlate it with prognosis. PDGFRs expression was evaluated by immunohistochemistry on 48 cases of formalin-fixed CMM samples and correlated with clinical-pathological findings and outcome after surgery. PDGFRs co-expression was observed in 37.5% of cases. Positivity for PDGFR-α and -β receptor was present in 54.2 and 47.9% of cases, respectively. Ki67 values >19.5% were ascertained in 66.7% of cases. Statistical analysis showed that PDGFRs co-expression and Ki67 values > 19.5% were both associated with worse prognosis. PDGFRs expression suggests a role in the pathogenesis and progression of CMM, and α and β co-expression appears to be associated to worse prognosis
2017
15
2
462
469
canine malignant melanomas, PDGFRs, target therapy
Iussich, Selina; Maniscalco, Lorella; Sciuva, Antonella Di; Iotti, Bryan; Morello, Emanuela; Martano, Marina; Gattino, Francesca; Buracco, Paolo; De Maria, Raffaella
File in questo prodotto:
File Dimensione Formato  
VCO_12190-corrected proof.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 843.32 kB
Formato Adobe PDF
843.32 kB Adobe PDF Visualizza/Apri
Morello 2vco.12190.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 544.66 kB
Formato Adobe PDF
544.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1530759
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact